• Healthy Living
France: Drugmaker on trial, suspected in deaths
French drugmaker suspected in deaths

The makers of a diabetes and weight loss drug suspected in the …

Health group didn't disclose HIV tests, apologizes
Health group didn't disclose HIV tests

Kaiser Permanente Northwest is apologizing to nearly 6,500 …

Ostomy saved me from a life in the bathroom
Ostomy saved me from a life in bathroom

Doug Yakich had a life-changing colostomy about two years ago. …

Another round for the House on 'Obamacare'
Another round for the House on ACA

Only months away from the rollout of coverage for uninsured …

Study: Malaria-infected mosquitoes more attracted to human odor
Malaria, mosquitoes and human odor

Scientists are exploring how the malaria parasite itself may …

Advertisement

Lilly drug chosen for Alzheimer's prevention study

Drug shows promise for milder forms of disease

Updated: Friday, 18 Jan 2013, 4:17 PM EST
Published : Friday, 18 Jan 2013, 4:17 PM EST

(AP) - Researchers have chosen an experimental drug by Eli Lilly & Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.

The drug, called solanezumab, is designed to bind to and help clear the sticky deposits that clog patients' brains.

Earlier studies found it did not help people with moderate to severe Alzheimer's but it showed some promise against milder disease. Researchers think it might work better if given before symptoms start.

"The hope is we can catch people before they decline," which can come 10 years or more after plaques first show up in the brain, said Dr. Reisa Sperling, director of the Alzheimer's center at Brigham and Women's Hospital in Boston.

She will help lead the new study, which will involve 1,000 people ages 70 to 85 whose brain scans show plaque buildup but who do not yet have any symptoms of dementia. They will get monthly infusions of solanezumab or a dummy drug for three years. The main goal will be slowing the rate of cognitive decline. The study will be done at 50 sites in the U.S. and possibly more in Canada, Australia and Europe, Sperling said.

In October, researchers said combined results from two studies of solanezumab suggested it might modestly slow mental decline, especially in patients with mild disease. Taken separately, the studies missed their main goals of significantly slowing the mind-robbing disease or improving activities of daily living.

Those results were not considered good enough to win the drug approval. So in December, Lilly said it would start another large study of it this year to try to confirm the hopeful results seen patients with mild disease. That is separate from the federal study Sperling will head.

About 35 million people worldwide have dementia, and Alzheimer's is the most common type. In the U.S., about 5 million have Alzheimer's. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.

Online:

Alzheimer's info: http://www.alzheimers.gov

Alzheimer's Association: http://www.alz.org

blog comments powered by Disqus
Advertisement
Advertisement